Biocept Stock Price, News & Analysis (NASDAQ:BIOC)

$0.70 0.00 (0.00 %)
(As of 12/13/2017 03:58 AM ET)
Previous Close$0.70
Today's Range$0.68 - $0.72
52-Week Range$0.60 - $3.39
Volume448,700 shs
Average Volume1.33 million shs
Market Capitalization$26.03 million
P/E RatioN/A
Dividend YieldN/A
Beta2.78

About Biocept (NASDAQ:BIOC)

Biocept logoBiocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic & Testing Substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200

Debt

Debt-to-Equity Ratio0.24%
Current Ratio1.41%
Quick Ratio1.27%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.22 million
Price / Sales7.65
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book17.50

Profitability

Trailing EPS($0.89)
Net Income$-18,390,000.00
Net Margins-375.28%
Return on Equity-359.21%
Return on Assets-157.08%

Miscellaneous

Employees70
Outstanding Shares35,180,000

Biocept (NASDAQ:BIOC) Frequently Asked Questions

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How were Biocept's earnings last quarter?

Biocept Inc (NASDAQ:BIOC) announced its quarterly earnings results on Tuesday, August, 2nd. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.02. The medical research company earned $0.66 million during the quarter, compared to analysts' expectations of $0.37 million. Biocept had a negative net margin of 375.28% and a negative return on equity of 359.21%. View Biocept's Earnings History.

When will Biocept make its next earnings announcement?

Biocept is scheduled to release their next quarterly earnings announcement on Monday, March, 5th 2018. View Earnings Estimates for Biocept.

Where is Biocept's stock going? Where will Biocept's stock price be in 2017?

3 analysts have issued twelve-month price objectives for Biocept's stock. Their forecasts range from $1.50 to $3.00. On average, they anticipate Biocept's stock price to reach $2.25 in the next twelve months. View Analyst Ratings for Biocept.

Who are some of Biocept's key competitors?

Who are Biocept's key executives?

Biocept's management team includes the folowing people:

  • Michael W. Nall, President, Chief Executive Officer, Director (Age 53)
  • Timothy C. Kennedy, Chief Financial Officer and Senior Vice President of Operations
  • Lyle J. Arnold Ph. D., Senior Vice President - Research & Development, Chief Scientific Officer (Age 69)
  • Veena Singh M.D., Senior Vice President, Senior Medical Director (Age 41)
  • Michael Terry, Senior Vice President - Commercial Operations
  • Raaj Trivedi, Vice President - Commercial Operations (Age 43)
  • David S. Moskowitz, Vice President - Strategy and Corporate Communications (Age 53)
  • David F. Hale, Non-Executive Chairman of the Board (Age 67)
  • Marsha A. Chandler Ph.D., Independent Director (Age 71)
  • Bruce E. Gerhardt CPA, Independent Director (Age 65)

Who owns Biocept stock?

Biocept's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include SABBY MANAGEMENT, LLC (9.20%) and SABBY MANAGEMENT, LLC (9.20%). Company insiders that own Biocept stock include Bruce Gerhardt, Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Institutional Ownership Trends for Biocept.

How do I buy Biocept stock?

Shares of Biocept can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocept's stock price today?

One share of Biocept stock can currently be purchased for approximately $0.70.

How big of a company is Biocept?

Biocept has a market capitalization of $26.03 million and generates $3.22 million in revenue each year. The medical research company earns $-18,390,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Biocept employs 70 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 NANCY RIDGE DR, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]


MarketBeat Community Rating for Biocept (BIOC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Biocept (NASDAQ:BIOC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.25$2.50$2.50$2.88
Price Target Upside: 251.56% upside78.57% upside78.57% upside38.22% upside

Biocept (NASDAQ:BIOC) Consensus Price Target History

Price Target History for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ:BIOC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017Chardan CapitalReiterated RatingBuy -> Buy$2.50 -> $1.50N/AView Rating Details
8/3/2017Westpark CapitalReiterated RatingOutperformLowView Rating Details
3/13/2017Roth CapitalReiterated RatingBuy$1.60 -> $3.00LowView Rating Details
11/10/2016Feltl & Co.UpgradeHold -> Buy$2.00N/AView Rating Details
8/31/2016Rodman & RenshawSet Price TargetBuy$2.50N/AView Rating Details
1/10/2016HC WainwrightReiterated RatingBuy$4.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Biocept (NASDAQ:BIOC) Earnings History and Estimates Chart

Earnings by Quarter for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ BIOC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018N/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.21)$1.23 million$1.28 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.34)($0.27)$1.26 million$1.29 millionViewListenView Earnings Details
11/9/2016Q316($0.57)($0.57)$0.76 million$1.05 millionViewListenView Earnings Details
8/2/2016Q216($0.22)($0.20)$0.37 million$0.66 millionViewN/AView Earnings Details
5/12/2016Q116($0.23)($0.25)$0.48 million$0.22 millionViewListenView Earnings Details
3/9/2016Q415($0.26)($0.24)$76.00 million$218.00 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.24)$0.78 million$0.17 millionViewN/AView Earnings Details
8/10/2015Q215($0.23)($0.22)$19.25 million$76.77 millionViewListenView Earnings Details
5/12/2015Q115($0.61)($0.37)$0.30 million$0.15 millionViewListenView Earnings Details
3/9/2015Q414($0.88)($0.87)$0.30 million$0.08 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.82)($0.87)$0.40 million$0.01 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.67)($0.67)$0.10 million$0.02 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Biocept (NASDAQ:BIOC) Earnings Estimates

2017 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.22)($0.19)($0.21)
Q2 20172($0.21)($0.19)($0.20)
Q3 20172($0.21)($0.17)($0.19)
Q4 20172($0.20)($0.18)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biocept (NASDAQ:BIOC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Biocept (NASDAQ BIOC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 7.99%
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)
Insider Trades by Quarter for Biocept (NASDAQ:BIOC)

Biocept (NASDAQ BIOC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/19/2016Claire ReissMajor ShareholderBuy227,272$1.10$249,999.20View SEC Filing  
10/19/2016David F. HaleDirectorBuy90,909$1.10$99,999.90View SEC Filing  
10/19/2016Lyle J. ArnoldSVPBuy45,000$1.10$49,500.00View SEC Filing  
10/19/2016Timothy KennedyCFOBuy36,363$1.10$39,999.30View SEC Filing  
5/4/2016Bruce GerhardtDirectorBuy25,000$1.00$25,000.00View SEC Filing  
5/4/2016Claire ReissMajor ShareholderBuy614,273$1.00$614,273.00View SEC Filing  
2/13/2015David F HaleChairmanBuy40,000$1.25$50,000.00View SEC Filing  
2/13/2015Marsha Alpert ChandlerDirectorBuy2,000$1.25$2,500.00View SEC Filing  
2/13/2015Michael W NallCEOBuy12,000$1.25$15,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Biocept (NASDAQ BIOC) News Headlines

Source:
DateHeadline
ETFs with exposure to Biocept, Inc. : December 11, 2017ETFs with exposure to Biocept, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:37 PM
Mid-Day Market Update: Crude Oil Down 1.5%; AeroVironment Shares Climb After Strong Q2 ResultsMid-Day Market Update: Crude Oil Down 1.5%; AeroVironment Shares Climb After Strong Q2 Results
www.nasdaq.com - December 6 at 3:38 PM
BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In BioceptBRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept
www.reuters.com - December 6 at 3:38 PM
What Spooked Biocept Inc (BIOC) Investors TodayWhat Spooked Biocept Inc (BIOC) Investors Today
finance.yahoo.com - December 6 at 3:38 PM
What Spooked Biocept Inc (BIOC) Investors TodayWhat Spooked Biocept Inc (BIOC) Investors Today
finance.yahoo.com - December 6 at 3:38 PM
Global Liquid Biopsy Market, Analysis and Forecast, 2017-2025Global Liquid Biopsy Market, Analysis and Forecast, 2017-2025
finance.yahoo.com - December 6 at 8:47 AM
Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.Today’s Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc.
finance.yahoo.com - December 6 at 8:47 AM
Biocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common StockBiocept Announces Pricing of Public Offering of up to 4,925,936 Shares of Common Stock
finance.yahoo.com - December 6 at 8:47 AM
Biocept (BIOC) Secures Patent on Target Selector Oncogene ... - StreetInsider.comBiocept (BIOC) Secures Patent on Target Selector Oncogene ... - StreetInsider.com
www.streetinsider.com - December 5 at 6:02 PM
Biocept Inc Shares Skyrocket on Surprise Patent VictoryBiocept Inc Shares Skyrocket on Surprise Patent Victory
finance.yahoo.com - December 5 at 6:02 PM
Biocept (BIOC) Secures Patent on Target Selector Oncogene Mutation Enrichment & Detection Liquid Biopsy ctDNA PlatformBiocept (BIOC) Secures Patent on Target Selector Oncogene Mutation Enrichment & Detection Liquid Biopsy ctDNA Platform
www.streetinsider.com - December 5 at 1:02 PM
First U.S. Patent Issued for Biocepts Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA PlatformFirst U.S. Patent Issued for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform
finance.yahoo.com - December 5 at 1:02 PM
Comparing Biocept (BIOC) and IRIS International (IRIS)Comparing Biocept (BIOC) and IRIS International (IRIS)
www.americanbankingnews.com - December 2 at 9:38 AM
Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocepts ... - PR Newswire (press release)Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 3:37 PM
ETFs with exposure to Biocept, Inc. : November 29, 2017ETFs with exposure to Biocept, Inc. : November 29, 2017
finance.yahoo.com - November 29 at 11:25 AM
Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 11:25 AM
Biocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocepts Liquid Biopsy Test in ImmunotherapyBiocept and UC San Diego Medical Center Announce Clinical Study Collaboration to Demonstrate Utility of Biocept's Liquid Biopsy Test in Immunotherapy
finance.yahoo.com - November 28 at 3:37 PM
Financial Contrast: Biocept (BIOC) versus IRIS International (IRIS)Financial Contrast: Biocept (BIOC) versus IRIS International (IRIS)
www.americanbankingnews.com - November 23 at 5:46 PM
Biocept, Inc. (BIOC) Rating Increased to Hold at Zacks Investment ResearchBiocept, Inc. (BIOC) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - November 22 at 5:10 PM
Lab-Developed Tests Fill Important Gap in Oncology Testing: Kalorama ReportLab-Developed Tests Fill Important Gap in Oncology Testing: Kalorama Report
www.bizjournals.com - November 20 at 8:23 PM
Zacks Investment Research Lowers Biocept, Inc. (BIOC) to SellZacks Investment Research Lowers Biocept, Inc. (BIOC) to Sell
www.americanbankingnews.com - November 15 at 5:06 PM
Contrasting Biocept (BIOC) & IRIS International (IRIS)Contrasting Biocept (BIOC) & IRIS International (IRIS)
www.americanbankingnews.com - November 14 at 1:50 PM
Biocept, Inc. (BIOC) Given New $1.50 Price Target at Chardan CapitalBiocept, Inc. (BIOC) Given New $1.50 Price Target at Chardan Capital
www.americanbankingnews.com - November 14 at 8:46 AM
ETFs with exposure to Biocept, Inc. : November 13, 2017ETFs with exposure to Biocept, Inc. : November 13, 2017
finance.yahoo.com - November 14 at 1:00 AM
Reviewing Biocept (BIOC) & IRIS International (IRIS)Reviewing Biocept (BIOC) & IRIS International (IRIS)
www.americanbankingnews.com - November 11 at 7:16 PM
Biocept, Inc. to Host Earnings CallBiocept, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 5:42 PM
Biocept Reports Third Quarter 2017 Financial ResultsBiocept Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:42 PM
Biocept, Inc. (BIOC) Receives Consensus Recommendation of "Hold" from AnalystsBiocept, Inc. (BIOC) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 6 at 1:18 AM
Biocept to Release Third Quarter Financial Results and Host ... - PR Newswire (press release)Biocept to Release Third Quarter Financial Results and Host ... - PR Newswire (press release)
www.prnewswire.com - November 3 at 8:33 AM
Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2017
finance.yahoo.com - November 2 at 5:13 PM
ETFs with exposure to Biocept, Inc. : November 2, 2017ETFs with exposure to Biocept, Inc. : November 2, 2017
finance.yahoo.com - November 2 at 5:13 PM
Biocept, Inc. (BIOC) Scheduled to Post Earnings on TuesdayBiocept, Inc. (BIOC) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
ETFs with exposure to Biocept, Inc. : October 23, 2017ETFs with exposure to Biocept, Inc. : October 23, 2017
finance.yahoo.com - October 23 at 5:28 PM
Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and HospitalsBiocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals
finance.yahoo.com - October 18 at 5:48 PM
Biocept, Inc. (BIOC) Rating Increased to Sell at ValuEngineBiocept, Inc. (BIOC) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - October 16 at 10:36 PM
Biocept, Inc. (BIOC) Short Interest Down 42.8% in SeptemberBiocept, Inc. (BIOC) Short Interest Down 42.8% in September
www.americanbankingnews.com - October 14 at 2:04 AM
Zacks Investment Research Upgrades Biocept, Inc. (BIOC) to "Hold"Zacks Investment Research Upgrades Biocept, Inc. (BIOC) to "Hold"
www.americanbankingnews.com - October 13 at 5:10 PM
Biocept, Inc. (BIOC) Receives Consensus Rating of "Hold" from BrokeragesBiocept, Inc. (BIOC) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 12 at 2:44 AM
Renowned Lung Cancer Expert Fred R. Hirsch, MD, Ph.D. Joins Biocepts Clinical Advisory Board - PR Newswire (press release)Renowned Lung Cancer Expert Fred R. Hirsch, MD, Ph.D. Joins Biocept's Clinical Advisory Board - PR Newswire (press release)
www.prnewswire.com - October 11 at 11:05 PM
Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocepts Clinical Advisory BoardRenowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept's Clinical Advisory Board
finance.yahoo.com - October 11 at 6:03 PM
ETFs with exposure to Biocept, Inc. : October 10, 2017ETFs with exposure to Biocept, Inc. : October 10, 2017
finance.yahoo.com - October 10 at 5:50 PM
ETFs with exposure to Biocept, Inc. : October 10, 2017ETFs with exposure to Biocept, Inc. : October 10, 2017
finance.yahoo.com - October 10 at 5:50 PM
What You Must Know About Biocept Inc’s (BIOC) RisksWhat You Must Know About Biocept Inc’s (BIOC) Risks
finance.yahoo.com - October 5 at 8:00 AM
Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States - PR Newswire (press release)Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States - PR Newswire (press release)
www.prnewswire.com - October 4 at 1:14 PM
Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 4 at 1:14 PM
BRIEF-Biocept and Miraca Life Sciences enter into marketing agreementBRIEF-Biocept and Miraca Life Sciences enter into marketing agreement
www.reuters.com - October 3 at 4:22 PM
Biocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United StatesBiocept and Miraca Life Sciences Enter Into Marketing Agreement to Expand Target Selector Testing in the United States
finance.yahoo.com - October 3 at 4:22 PM
 Brokerages Expect Biocept, Inc. (BIOC) Will Announce Quarterly Sales of $1.40 Million Brokerages Expect Biocept, Inc. (BIOC) Will Announce Quarterly Sales of $1.40 Million
www.americanbankingnews.com - September 28 at 1:56 PM
5 Medtech Stocks to Steer Clear of Amid Political Chaos - Nasdaq5 Medtech Stocks to Steer Clear of Amid Political Chaos - Nasdaq
www.nasdaq.com - September 20 at 2:33 AM
5 Medtech Stocks to Steer Clear of Amid Political Chaos5 Medtech Stocks to Steer Clear of Amid Political Chaos
finance.yahoo.com - September 19 at 4:31 PM

SEC Filings

Biocept (NASDAQ:BIOC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Biocept (NASDAQ:BIOC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Biocept (NASDAQ BIOC) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.